Rallybio Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $646K+1.6% YoYTTM through 30 Jun 2026
Net Income $45.6MTTM through 30 Jun 2026
Free Cash Flow $26.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -3,915.1% |
| Net Margin | 7,051.2% |
Returns
-15.7%ROE
-14.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio12.92x
Net Debt-$21.9Mnet cash position
Cash & Equivalents$92.8M
Quality Metrics
Altman Z-Score11.53
Piotroski F-Score5 / 9
FCF Margin4,135.0%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $858K
Diluted EPS$5.00TTMFY2025: $-1.59
Dividend
No dividend
Capital Allocation
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Rare Disease Therapeutics | $212K | +6.0% | View detailsRefocusing operations and pipeline development under the proposed merger with Avenzo Therapeutics, announced in June 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.